Survey Administration for Cancer

Phase-Based Progress Estimates
Fred Hutch/University of Washington Cancer Consortium, Seattle, WACancerSurvey Administration - Other
All Sexes
What conditions do you have?

Study Summary

This trial compares two treatments for weight loss in overweight or obese people. One treatment is standard behavioral therapy, and the other is called Acceptance and Commitment Therapy. Acceptance and Commitment Therapy focuses on being willing to experience physical cravings, emotions, and thoughts while making values-guided committed behavior changes. This trial will see if Acceptance and Commitment Therapy is better at improving weight loss compared to standard behavioral therapy.

Eligible Conditions
  • Obesity-Related Cancer

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: At 6, 12, and 24-months post randomization

Month 12
10% or more weight loss
At 6, 12, and 24-months post randomization
Dietary intake
Percent weight change
Physical activity
Trajectories of weight change

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Arm II (SBT)
1 of 2
Arm I (ACT)
1 of 2

Active Control

Experimental Treatment

398 Total Participants · 2 Treatment Groups

Primary Treatment: Survey Administration · No Placebo Group · Phase 3

Arm I (ACT)Experimental Group · 2 Interventions: Survey Administration, Telephone-Based Intervention · Intervention Types: Other, Behavioral
Arm II (SBT)ActiveComparator Group · 2 Interventions: Survey Administration, Telephone-Based Intervention · Intervention Types: Other, Behavioral
First Studied
Drug Approval Stage
How many patients have taken this drug
Telephone-Based Intervention
Completed Phase 2

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: at 6, 12, and 24-months post randomization

Who is running the clinical trial?

Fred Hutchinson Cancer Research CenterLead Sponsor
443 Previous Clinical Trials
148,789 Total Patients Enrolled
Fred Hutchinson Cancer CenterLead Sponsor
532 Previous Clinical Trials
1,314,869 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,186 Previous Clinical Trials
4,089,491 Total Patients Enrolled
Jonathan B BrickerPrincipal InvestigatorFred Hutch/University of Washington Cancer Consortium

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You weigh more than what is considered healthy for your height, but not more than a certain limit.
You want to lose weight within the next month.
You are willing to be randomly selected for either group in the study.
You live in the United States.
You have a phone and email that you can check every day.
You want to learn how to lose weight.
You are not pregnant, planning to get pregnant, or breastfeeding in the next 12 months.
You have not lost more than 5% of your body weight in the last 6 months.
You do not have any medical or mental conditions that would make it difficult for you to follow the weight loss program or put you at risk during the process. This includes conditions such as binge eating disorder, severe depression, serious heart disease, uncontrolled hypertension, diabetes, or cancer. If you have any of these conditions, you will need written approval from your doctor to participate.
You changed the amount of certain medications that can affect your weight or appetite within the last 3 months.

Who else is applying?

What state do they live in?
What site did they apply to?
Fred Hutch/University of Washington Cancer Consortium100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
How many prior treatments have patients received?

Frequently Asked Questions

Is the Survey Administration process in line with FDA regulations?

"Survey Administration has been studied in a Phase 3 trial, so there is some data supporting its efficacy and multiple rounds of data supporting its safety." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.